{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:06:58Z","timestamp":1792210018717,"version":"4.4.0"},"reference-count":90,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"departmental sources and the program \u201cInvestissements d\u2019Avenir\u201d","award":["ANR-11-LABX-0021"],"award-info":[{"award-number":["ANR-11-LABX-0021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Acute heart failure and cardiogenic shock are frequently occurring and deadly conditions. In patients with those conditions, endotoxemia related to gut injury and gut barrier dysfunction is usually described as a driver of organ dysfunction. Because endotoxemia might reciprocally alter cardiac function, this phenomenon has been suggested as a potent vicious cycle that worsens organ perfusion and leading to adverse outcomes. Yet, evidence beyond this phenomenon might be overlooked, and mechanisms are not fully understood. Subsequently, even though therapeutics available to reduce endotoxin load, there are no indications to treat endotoxemia during acute heart failure and cardiogenic shock. In this review, we first explore the evidence regarding endotoxemia in acute heart failure and cardiogenic shock. Then, we describe the main treatments for endotoxemia in the acute setting, and we present the challenges that remain before personalized treatments against endotoxemia can be used in patients with acute heart failure and cardiogenic shock.<\/jats:p>","DOI":"10.3390\/jcm12072579","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T01:31:30Z","timestamp":1680139890000},"page":"2579","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Endotoxemia in Acute Heart Failure and Cardiogenic Shock: Evidence, Mechanisms and Therapeutic Options"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-1487","authenticated-orcid":false,"given":"Maxime","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Dijon University Hospital, F-21000 Dijon, France"},{"name":"Universit\u00e9 Bourgogne-Franche Comt\u00e9, UMR1231, F-21000 Dijon, France"},{"name":"INSERM, UMR1231, F-21000 Dijon, France"},{"name":"LipSTIC LabEx, F-21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1119-7382","authenticated-orcid":false,"given":"Thomas","family":"Gautier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Bourgogne-Franche Comt\u00e9, UMR1231, F-21000 Dijon, France"},{"name":"INSERM, UMR1231, F-21000 Dijon, France"},{"name":"LipSTIC LabEx, F-21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Masson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Bourgogne-Franche Comt\u00e9, UMR1231, F-21000 Dijon, France"},{"name":"INSERM, UMR1231, F-21000 Dijon, France"},{"name":"LipSTIC LabEx, F-21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belaid","family":"Bouhemad","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Dijon University Hospital, F-21000 Dijon, France"},{"name":"Universit\u00e9 Bourgogne-Franche Comt\u00e9, UMR1231, F-21000 Dijon, France"},{"name":"INSERM, UMR1231, F-21000 Dijon, France"},{"name":"LipSTIC LabEx, F-21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7019-9727","authenticated-orcid":false,"given":"Pierre-Gr\u00e9goire","family":"Guinot","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Dijon University Hospital, F-21000 Dijon, France"},{"name":"Universit\u00e9 Bourgogne-Franche Comt\u00e9, UMR1231, F-21000 Dijon, France"},{"name":"INSERM, UMR1231, F-21000 Dijon, France"},{"name":"LipSTIC LabEx, F-21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.healun.2020.02.004","article-title":"Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant","volume":"39","author":"Yuzefpolskaya","year":"2020","journal-title":"J. Heart Lung Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0741-5214(93)90341-I","article-title":"Endotoxemia after major vascular operations","volume":"18","author":"Roumen","year":"1993","journal-title":"J. Vasc. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1056\/NEJM198908033210503","article-title":"The cardiovascular response of normal humans to the administration of endotoxin","volume":"321","author":"Suffredini","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/eurheartj\/ehi389","article-title":"The importance of the gastrointestinal system in the pathogenesis of heart failure","volume":"26","author":"Krack","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.106.613596","article-title":"Cardiogenic shock current concepts and improving outcomes","volume":"117","author":"Reynolds","year":"2008","journal-title":"Circulation"},{"key":"ref_6","first-page":"365","article-title":"Effects of glucagon on regional blood flow during cardiogenic shock","volume":"6","author":"Sivarajan","year":"1979","journal-title":"Circ. Shock"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.15171\/jcvtr.2015.19","article-title":"The Effect of Lipopolysaccharide on Ischemic-Reperfusion Injury of Heart: A Double Hit Model of Myocardial Ischemia and Endotoxemia","volume":"7","author":"Nader","year":"2015","journal-title":"J. Cardiovasc. Thorac. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nri1004","article-title":"Innate immune sensing and its roots: The story of endotoxin","volume":"3","author":"Beutler","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13054-016-1458-3","article-title":"The digestive tract as the origin of systemic inflammation","volume":"20","author":"Jansen","year":"2016","journal-title":"Crit. Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1152\/ajplung.00477.2005","article-title":"NF-kappa B activation as a pathological mechanism of septic shock and inflammation","volume":"290","author":"Liu","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1753425918819754","article-title":"Comparison of different lots of endotoxin and evaluation of in vivo potency over time in the experimental human endotoxemia model","volume":"25","author":"Kiers","year":"2019","journal-title":"Innate Immun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40635-022-00471-6","article-title":"T cell dysregulation in inflammatory diseases in ICU","volume":"10","author":"Luperto","year":"2022","journal-title":"Intensive Care Med. Exp."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00046-17","DOI":"10.1128\/mSystems.00046-17","article-title":"Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling","volume":"2","author":"Abubucker","year":"2017","journal-title":"mSystems"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100302","DOI":"10.1016\/j.obmed.2020.100302","article-title":"Gut microbiome dysbiosis and endotoxemia\u2014Additional pathophysiological explanation for increased COVID-19 severity in obesity","volume":"20","year":"2020","journal-title":"Obes. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1194\/jlr.D059725","article-title":"Quantitative lipopolysaccharide analysis using HPLC\/MS\/MS and its combination with the limulus amebocyte lysate assay","volume":"56","author":"Gautier","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"bvz039","DOI":"10.1210\/jendso\/bvz039","article-title":"Intestinal barrier dysfunction, LPS translocation, and disease development","volume":"4","author":"Ghosh","year":"2020","journal-title":"J. Endocr. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.biochi.2010.04.016","article-title":"Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation","volume":"93","author":"Laugerette","year":"2011","journal-title":"Biochimie"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10620-019-05777-2","article-title":"The \u201cLeaky Gut\u201d: Tight Junctions but Loose Associations?","volume":"65","author":"Hollander","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1194\/jlr.M800156-JLR200","article-title":"Chylomicrons promote intestinal absorption of lipopolysaccharides","volume":"50","author":"Ghoshal","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1210\/jc.2015-2518","article-title":"Postprandial endotoxemia linked with chylomicrons and lipopolysaccharides handling in obese versus lean men: A lipid dose-effect trial","volume":"100","author":"Vors","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"108105","DOI":"10.1016\/j.pharmthera.2021.108105","article-title":"New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis","volume":"236","author":"Gautier","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3389\/fimmu.2021.622935","article-title":"Intra-Abdominal Lipopolysaccharide Clearance and Inactivation in Peritonitis: Key Roles for Lipoproteins and the Phospholipid Transfer Protein","volume":"12","author":"Nguyen","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1091-255X(99)80067-5","article-title":"Early increase in intestinal permeability in patients with severe acute pancreatitis: Correlation with endotoxemia, organ failure, and mortality","volume":"3","author":"Ammori","year":"1999","journal-title":"J. Gastrointest. Surg."},{"key":"ref_26","first-page":"138","article-title":"Intestinal permeability and systemic endotoxemia in patients with acute pancreatitis","volume":"87","author":"Schietroma","year":"2016","journal-title":"Ann. Ital. Chir."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jama.1996.03530370045029","article-title":"Intestinal Permeability, Gastric Intramucosal pH, and Systemic Endotoxemia in Patients Undergoing Cardiopulmonary Bypass","volume":"275","author":"Riddington","year":"1996","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/00000542-200106000-00030","article-title":"Pathophysiology, Clinical Manifestations, and Prevention of Ischemia-Reperfusion Injury","volume":"94","author":"Collard","year":"2001","journal-title":"Anesthesiology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1445-2197.1998.tb02099.x","article-title":"Ischaemia-reperfusion injury to the intestine","volume":"68","author":"Kong","year":"1998","journal-title":"Aust. N. Z. J. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2013.04.070","article-title":"Abdominal contributions to cardiorenal dysfunction in congestive heart failure","volume":"62","author":"Verbrugge","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ejhf.872","article-title":"Organ dysfunction, injury and failure in acute heart failure: From pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"19","author":"Harjola","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e12379","DOI":"10.1111\/micc.12379","article-title":"The impact of endotoxin on jejunal tissue oxygenation","volume":"24","author":"Pajk","year":"2017","journal-title":"Microcirculation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1046\/j.1365-2168.1998.00717.x","article-title":"Lower limb ischaemia-reperfusion injury causes endotoxaemia and endogenous antiendotoxin antibody consumption but not bacterial translocation","volume":"85","author":"Yassin","year":"1998","journal-title":"Br. J. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.hlc.2016.10.012","article-title":"Prolonged Cardiopulmonary Bypass is a Risk Factor for Intestinal Ischaemic Damage and Endotoxaemia","volume":"26","author":"Adamik","year":"2017","journal-title":"Heart Lung Circ."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.2353\/ajpath.2010.091069","article-title":"Human Intestinal Ischemia-Reperfusion\u2013Induced Inflammation Characterized: Experiences from a New Translational Model","volume":"176","author":"Grootjans","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_36","first-page":"152","article-title":"Biomarkers of gut barrier failure in the ICU","volume":"22","author":"Piton","year":"2016","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/SHK.0000000000001195","article-title":"Intestinal Fatty Acid Binding Protein is Associated With Mortality in Patients With Acute Heart Failure or Cardiogenic Shock","volume":"51","author":"Kastl","year":"2019","journal-title":"Shock"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1097\/CCM.0b013e31828c26b5","article-title":"Enterocyte damage in critically ill patients is associated with shock condition and 28-day mortality","volume":"41","author":"Piton","year":"2013","journal-title":"Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/SHK.0000000000000327","article-title":"Catecholamine use is associated with enterocyte damage in critically ill patients","volume":"43","author":"Piton","year":"2015","journal-title":"Shock"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/SHK.0b013e3181a2bcd6","article-title":"Systemic inflammation increases intestinal permeability during experimental human endotoxemia","volume":"32","author":"Hietbrink","year":"2009","journal-title":"Shock"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155182","DOI":"10.1016\/j.cyto.2020.155182","article-title":"Glucagon-like peptide-1 is associated with poor clinical outcome, lipopolysaccharide translocation and inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass","volume":"133","author":"Nguyen","year":"2020","journal-title":"Cytokine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.resuscitation.2012.06.010","article-title":"Markers of intestinal injury are associated with endotoxemia in successfully resuscitated patients","volume":"84","author":"Grimaldi","year":"2013","journal-title":"Resuscitation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2015.05.061","article-title":"Clinical and prognostic role of ammonia in advanced decompensated heart failure. The cardio-abdominal syndrome?","volume":"195","author":"Frea","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1152\/physrev.00003.2008","article-title":"Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer","volume":"91","author":"Fasano","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1590\/1806-9282.20220197","article-title":"The role of gut dysbiosis-associated inflammation in heart failure","volume":"68","author":"Siqueira","year":"2022","journal-title":"Rev. Assoc. Med. Bras"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.14336\/AD.2017.0630","article-title":"Serum Zonulin and Endotoxin Levels in Exceptional Longevity versus Precocious Myocardial Infarction","volume":"9","author":"Lindeberg","year":"2018","journal-title":"Aging Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40168-018-0441-4","article-title":"Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction","volume":"6","author":"Zhou","year":"2018","journal-title":"Microbiome"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0140-6736(98)09286-1","article-title":"Endotoxin and immune activation in chronic heart failure: A prospective cohort study","volume":"353","author":"Niebauer","year":"1999","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1388-9842(03)00104-1","article-title":"Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure","volume":"5","author":"Peschel","year":"2003","journal-title":"Eur. J. Heart Fail."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijcard.2010.12.016","article-title":"Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure","volume":"157","author":"Sandek","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0167-5273(99)00118-7","article-title":"Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: The potential importance of bacterial translocation","volume":"72","author":"Brunkhorst","year":"1999","journal-title":"Int. J. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/SHK.0000000000000798","article-title":"Septic Participation in Cardiogenic Shock: Exposure to Bacterial Endotoxin","volume":"47","author":"Ramirez","year":"2017","journal-title":"Shock"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.ijcard.2012.11.100","article-title":"Endotoxin role in cardiogenic shock: A brief report","volume":"167","author":"Lazzeri","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3389\/fmed.2021.772413","article-title":"Endotoxin Activity in Patients With Extracorporeal Membrane Oxygenation Life Support: An Observational Pilot Study","volume":"8","author":"Lee","year":"2021","journal-title":"Front. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00134-019-05749-0","article-title":"Improved quantification of plasma lipopolysaccharide (LPS) burden in sepsis using 3-hydroxy myristate (3HM): A cohort study","volume":"45","author":"Dargent","year":"2019","journal-title":"Intensive Care Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1161\/01.CIR.0000075927.67673.F2","article-title":"Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm","volume":"107","author":"Hochman","year":"2003","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","article-title":"PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock","volume":"377","author":"Thiele","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-2780-3","article-title":"Therapeutic Potential of the Gut Microbiota in the Management of Sepsis","volume":"24","author":"Bassetti","year":"2020","journal-title":"Crit. Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4291\/wjgp.v12.i6.106","article-title":"Bacterial translocation in patients undergoing major gastrointestinal surgery and its role in postoperative sepsis","volume":"12","author":"Doudakmanis","year":"2021","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.3389\/fcvm.2021.803744","article-title":"Gut Microbiota in Heart Failure Patients With Preserved Ejection Fraction (GUMPTION Study)","volume":"8","author":"Huang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00003246-200201000-00006","article-title":"No effect of preoperative selective gut decontamination on endotoxemia and cytokine activation during cardiopulmonary bypass: A randomized, placebo-controlled study","volume":"30","author":"Bouter","year":"2002","journal-title":"Crit. Care Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1097\/00003246-199311000-00017","article-title":"Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass?","volume":"21","author":"Merino","year":"1993","journal-title":"Crit. Care Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103511","DOI":"10.1016\/j.ebiom.2021.103511","article-title":"Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial","volume":"70","author":"Awoyemi","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00134-019-05649-3","article-title":"Impact of the route of nutrition on gut mucosa in ventilated adults with shock: An ancillary of the NUTRIREA-2 trial","volume":"45","author":"Piton","year":"2019","journal-title":"Intensive Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1073\/pnas.0712140105","article-title":"Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition","volume":"105","author":"Goldberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1473-3099(10)70220-6","article-title":"Endotoxin removal devices for the treatment of sepsis and septic shock","volume":"11","author":"Davies","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40635-018-0177-2","article-title":"In vitro comparison of the adsorption of inflammatory mediators by blood purification devices","volume":"6","author":"Malard","year":"2018","journal-title":"Intensive Care Med. Exp."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/jama.2009.856","article-title":"Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial","volume":"301","author":"Cruz","year":"2009","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","article-title":"Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: A multicenter randomized control trial","volume":"41","author":"Payen","year":"2015","journal-title":"Intensive Care Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2018.14618","article-title":"Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial","volume":"320","author":"Dellinger","year":"2018","journal-title":"JAMA"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Broman, M.E., Hansson, F., Vincent, J.-L., and Bodelsson, M. (2019). Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: A randomized crossover double-blind study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220444"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e030139","DOI":"10.1136\/bmjopen-2019-030139","article-title":"The premature closure of ROMPA clinical trial: Mortality reduction in septic shock by plasma adsorption","volume":"9","year":"2019","journal-title":"BMJ Open"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00134-021-06501-3","article-title":"High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: A multicentre, adaptive, randomised clinical trial","volume":"47","author":"Garbero","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"738496","DOI":"10.3389\/fcvm.2021.738496","article-title":"Evaluation of the Oxiris Membrane in Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation Support: Study Protocol for a Single Center, Single-Blind, Randomized Controlled Trial","volume":"8","author":"Andrei","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/00003246-199506000-00003","article-title":"A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial","volume":"23","author":"Bone","year":"1995","journal-title":"Crit. Care Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-121-1-199407010-00001","article-title":"Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial","volume":"121","author":"McCloskey","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/CCM.0b013e3181b07b78","article-title":"Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*","volume":"38","author":"Tidswell","year":"2010","journal-title":"Crit. Care Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jama.2013.2194","article-title":"Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis","volume":"309","author":"Opal","year":"2013","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","article-title":"Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock","volume":"351","author":"Abraham","year":"1998","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","article-title":"Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial","volume":"25","author":"Opal","year":"1997","journal-title":"Crit. Care Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1042\/BST0390984","article-title":"Plasma PLTP (phospholipid-transfer protein): An emerging role in \u201creverse lipopolysaccharide transport\u201d and innate immunity","volume":"39","author":"Gautier","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/ALN.0000000000003155","article-title":"Reconstituted high-density lipoprotein therapy improves survival in mouse models of sepsis","volume":"132","author":"Tanaka","year":"2020","journal-title":"Anesthesiology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1084\/jem.184.5.1601","article-title":"Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia","volume":"184","author":"Pajkrt","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J. Innate Immun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1097\/CCM.0b013e3181b0266c","article-title":"Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial","volume":"37","author":"Tomayko","year":"2009","journal-title":"Crit. Care Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/s41598-017-03285-9","article-title":"Recombinant human plasma phospholipid transfer protein (PLTP) to prevent bacterial growth and to treat sepsis","volume":"7","author":"Deckert","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/01.CCM.0000059724.08290.51","article-title":"Lipoprotein metabolism in patients with severe sepsis","volume":"31","author":"Heezius","year":"2003","journal-title":"Crit. Care Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1023\/B:DDAS.0000042232.98927.91","article-title":"Ischemia-Reperfusion Injury of the Intestine and Protective Strategies Against Injury","volume":"49","author":"Yang","year":"2004","journal-title":"Dig. Dis. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00134-018-5462-8","article-title":"What\u2019s new in immunostimulating strategies in the ICU","volume":"45","author":"Pickkers","year":"2019","journal-title":"Intensive Care Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2579\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:06:04Z","timestamp":1760123164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":90,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12072579"],"URL":"https:\/\/doi.org\/10.3390\/jcm12072579","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]}}}